Trial Profile
Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime Administered as Single IV Doses in Healthy Human Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Dec 2016
Price :
$35
*
At a glance
- Drugs Zidebactam (Primary) ; Cefepime
- Indications Gram-negative infections
- Focus Adverse reactions
- Sponsors Wockhardt
- 30 Oct 2016 Results assessing safety and pharmacokinetics of Zidebactam presented at the IDWeek 2016
- 02 May 2016 Status changed from active, no longer recruiting to completed.
- 28 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.